Chemical Conjugation in Drug Delivery Systems

Eras, Alexis; Castillo, Danna; Suárez, Margarita; Vispo, Nelson Santiago; Alberício, Fernando; Rodríguez, Hortensia

doi:10.3389/fchem.2022.889083

Cited by 21 publications

(11 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extensive literature highlights a variety of strategies for self-attachment and/or conjugation of modified nanoparticles with toxic chemotherapy drugs like duxorubin, CB7-cisplatin, and CB6-nedaplatin, involving hydrogen bonding, covalent bonding, Amine-carboxyl bonding, hydrophobic interactions, electrostatic interactions, π–π stacking, and van der Waals forces 22 , 31 – 33 . Consequently, the functionalized AgNPs obtained in our study demonstrate significant potential for physical and chemical conjugation with toxic drugs 32 , 33 . (Fig.…”

Section: Synthesis and Characterization Of Agnp In Hybrid Aqueous Nan...mentioning

confidence: 83%

Ultra-stable nano-micro bubbles in a biocompatible medium for safe delivery of anti-cancer drugs

Bunyatova,

Dogan,

Tekin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

We conducted a series of experimental investigations to generate laser-stimulated millimeter bubbles (MBs) around silver nanoparticles (AgNPs) and thoroughly examined the mechanism of bubble formation within this nanocomposite system. One crucial aspect we explored was the lifetime and kinetics of these bubbles, given that bubbles generated by plasmonic nanoparticles are known to be transient with short durations. Surprisingly, our findings revealed that the achieved lifetime of these MBs extended beyond seven days. This impressive longevity far surpasses what has been reported in the existing literature. Further analysis of the experimental data uncovered a significant correlation between bubble volume and its lifetime. Smaller bubbles demonstrated longer lifetimes compared to larger ones, which provided valuable insights for future applications. The experimental results not only confirmed the validity of our model and simulations but also highlighted essential characteristics, including extended lifetime, matching absorption coefficients, adherence to physical boundary conditions, and agreement with simulated system parameters. Notably, we generated these MBs around functionalized AgNPs in a biocompatible nanocomposite medium by utilizing low-power light excitation. By readily binding potent cancer drugs to AgNPs through simple physical mixing, these medications can be securely encapsulated within bubbles and precisely guided to targeted locations within the human body. This capability to deliver drugs directly to the tumor site, while minimizing contact with healthy tissues, can lead to improved treatment outcomes and reduced side effects, significantly enhancing the quality of life for cancer patients.

show abstract

Section: Synthesis and Characterization Of Agnp In Hybrid Aqueous Nan...mentioning

confidence: 83%

Ultra-stable nano-micro bubbles in a biocompatible medium for safe delivery of anti-cancer drugs

Bunyatova,

Dogan,

Tekin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…As one of the most difficult aspects of developing ADCs, the selection of linkers is critical, as it promotes the biological coupling reaction. Linkers can prevent the premature release of drugs, improve the release of active drugs at the target and promote the stability of the production process ( 37 ). At present, ADC linkers that have been listed and are in clinical trials can be mainly divided into two categories, namely, cleavable linkers and non-cleavable linkers ( Table 1 ).…”

Section: Discussionmentioning

confidence: 99%

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis

Yao

Zhang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveAntibody-drugs conjugates (ADCs) are novel drugs with highly targeted and tumor-killing abilities and developing rapidly. This study aimed to evaluate drug discovery and clinical trials of and explore the hotspots and frontiers from 2012 to 2022 using bibliometric methods.MethodsPublications on ADCs were retrieved between 2012 and 2022 from Web of Science (WoS) and analyzed with CiteSpace 6.1.R2 software for the time, region, journals, institutions, etc. Clinical trials were downloaded from clinical trial.org and visualized with Excel software.ResultsA total of 696 publications were obtained and 187 drug trials were retrieved. Since 2012, research on ADCs has increased year by year. Since 2020, ADC-related research has increased dramatically, with the number of relevant annual publications exceeding 100 for the first time. The United States is the most authoritative and superior country and region in the field of ADCs. The University of Texas MD Anderson Cancer Center is the most authoritative institution in this field. Research on ADCs includes two clinical trials and one review, which are the most influential references. Clinical trials of ADCs are currently focused on phase I and phase II. Comprehensive statistics and analysis of the published literature and clinical trials in the field of ADCs, have shown that the most studied drug is brentuximab vedotin (BV), the most popular target is human epidermal growth factor receptor 2 (HER2), and breast cancer may become the main trend and hotspot for ADCs indications in recent years.ConclusionAntibody-drug conjugates have become the focus of targeted therapies in the field of oncology. The innovation of technology and combination application strategy will become the main trend and hotspots in the future.

show abstract

“…[1] ADCs comprise four segments: the monoclonal antibody, payload, linker, and conjugation site. [6,7] To allow drug delivery to specific targets, the monoclonal antibody must have specific binding affinity for antigens that are highly expressed on tumor cells. This enables the ADC to act as a drug delivery system.…”

Section: Overview Of Antibodyà Drug Conjugatesmentioning

confidence: 99%

“… [1–5] Currently, >10 ADCs are commercially available (Table 1) and >110 ADCs are under investigation in clinical trials [1] . ADCs comprise four segments: the monoclonal antibody, payload, linker, and conjugation site [6,7] . To allow drug delivery to specific targets, the monoclonal antibody must have specific binding affinity for antigens that are highly expressed on tumor cells.…”

Section: Overview Of Antibody−drug Conjugatesmentioning

confidence: 99%

Tag‐Free Enzymatic Modification for Antibody−Drug Conjugate Production

Yamazaki

Matsuda

2022

ChemistrySelect

View full text Add to dashboard Cite

Currently, although >10 antibody−drug conjugates (ADCs) are available in the market, most of them (10 ADCs) have broad drug distribution, thereby potentially limiting their therapeutic index. The ADC industry is shifting from random conjugation technology to site‐specific conjugation technology to overcome this issue. Enzymatic site‐specific conjugation is a promising cutting‐edge technology owing to its mild conjugation conditions. This review discussed enzymatic conjugation strategies for producing ADCs via modifying native antibodies without using a tag moiety. We described the comparison of the three main conjugation technologies used to produce site‐specific ADCs. Each of the three enzymatic approaches described in this review differs in their advantages and disadvantages, providing pharmaceutical companies the option to select an approach suitable to their purpose and/or target protein.

show abstract

Chemical Conjugation in Drug Delivery Systems

Cited by 21 publications

References 143 publications

Ultra-stable nano-micro bubbles in a biocompatible medium for safe delivery of anti-cancer drugs

Ultra-stable nano-micro bubbles in a biocompatible medium for safe delivery of anti-cancer drugs

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis

Tag‐Free Enzymatic Modification for Antibody−Drug Conjugate Production

Contact Info

Product

Resources

About